Magic Formula Investing 2010 Year In Review
Since the "bible" of MFI, The Little Book that Beats the Market, emphasizes including small caps to maximize the strategy's returns, below is a graph that shows the relative performance of MFI's "top 50 stocks over 50 million market cap" screen against the S&P 500 ETF (SPY). The results below assume that all 50 MFI stocks were purchased on a date and held until 12/23, and compares the average performance of all stocks in the screen to buying SPY on the same day. 52 samples were taken, on Wednesday of each week in 2010:
The largest gains from MFI came early in the year, particularly in February where the screen averaged almost 24% for each purchase, far out-performing the S&P's 14.8%. The worst performance came through April and the first part of May, where MFI trailed the S&P by 2.4% on average. In all, though, the strategy's success is evident. The formula out-performed the S&P in 41 of 52 samples, and for the entire year, the average MFI portfolio appreciated 13.1% vs. the S&P's 10.3%.
Also impressive was the "hit rate" of MFI. In just one of the 52 samples (the last one, 12/22) did the screen have under 50% of its stocks finish with positive gains. In 17 weeks, over 3/4 (75%) of stocks delivered positive gains to the end of the year. Put simply, there were very few duds in MFI this year, a stark contrast to what I've seen in the past.
MFI dug up some big winners for the year:
Magic Software (MGIC): MGIC's performance in 2010 was pretty magical. If you would have purchased the stock during its February run in the screen, you would have enjoyed nearly a four-bagger (300% appreciation). This Israeli cloud computing, "platform-as-a-service" provider was the single best performer of MFI in 2010.
Questcor Pharmaceuticals (QCOR): Questcor had similarly strong results, delivering over a triple (200%) from January listings in MFI. A purchase as late as mid-March would have doubled. In the review, I mentioned that this was a risky, but potentially lucrative, stock, given its dominance of a niche market. Competitive failures and new indications for its single drug Acthar has pushed the stock ever higher.
Synta Pharmaceuticals (SNTA): Synta is a classic example of the unpredictable nature of development stage drug companies. Frankly, I panned the stock in my review, as it lost its main candidate Elesclomol, had nothing out of phase 2 trials, and was burning a lot of cash. However, strong early results for STA-9090 have sent the stock sharply upwards. This is still a lottery ticket, but it is hard to argue with 130% gains from August.
CF Industries (CF): CF is up over 100% from May/June MFI purchases. The completion of the Terra Industries acquisition has given the firm a dominant market share in nitrate fertilizer, which plays perfectly into a now 3-year long agricultural bull market. Back in the spring, the market was concerned that CF overpaid for Terra, but recent results have buried those concerns for the time being.
SuperMedia (SPMD): This stock, both in current form and in its previous life as Idearc, has been kryptonite to MFI. It is down 80% from its appearance in the screen through February and March. This yellow pages publisher is the quintessential "bad Magic Formula stock".
Jackson Hewitt (JTX): Tax prep firm, down about 50% since appearing last January. The loss of refund anticipation loan funding, franchisee problems, a poor balance sheet, and a move towards self-filing has decimated this once solid company.
Chinese reverse take-over stocks (CSKI, CJJD, NEP, CEU, etc.): Most of these have declined 20%, at least, since showing up. Successful short attacks, fraud allegations, and an overall distrust of management and auditors has been the theme for 2010. I believe some may have been explicitly removed from the official screens due to fraud allegations. Statistically, it seems they should all be listed.
The Magic Formula Investing strategy continued its history of market-beating returns in 2010, and there is no reason not to expect more of the same in 2011.
Disclosure: Steve owns no stocks referenced here.
Joel Greenblatt and MagicFormulaInvesting.com are not associated in any way with this website. Neither Mr. Greenblatt or MagicFormulaInvesting.com endorse this website's investment opinions, strategy, or products. Investment recommendations on this website are not chosen by Mr. Greenblatt, nor are they based on Mr. Greenblatt's proprietary investment model, and are not chosen by MagicFormulaInvesting.com. Magic Formula® is a registered trademark of MagicFormulaInvesting.com, which has no connection to this website. The information on this website is for informational purposes only and solely represents the views and opinions of the author. No warranty is provided or implied as to the accuracy, completeness, or timeliness of this information. This information may not be construed as investment advice of any kind. The proprietor of this website is not responsible in any way for losses or damages resulting from the use of this information. Alexander Online Properties is not a registered investment advisor. All logos are trademarked properties of their respective companies.
© 2008-2013 Alexander Online Properties.